Better Buy: CRISPR Therapeutics vs. Intellia
The gene editing revolution is taking the market by storm, garnering the attention of large pharma companies and investors alike. This technology allows scientists to change an organism's DNA and can transform the way many diseases are treated. Only a handful of companies specialize in this area, and they offer investors substantial growth opportunities in a high-risk, high-reward field.
Both CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA) offer promising gene editing tools that could alter some medical treatments. Which of these two small-cap biotech stocks should you choose? The best way to evaluate these two companies is to start with their pipelines, so let's find out what each has to offer.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
